Why the Pros Are Passing on Encysive Pharma

Has Encysive Pharmaceuticals (ENCY Quote) finally convinced drug regulators to approve Thelin?

That's the burning question on the minds of Encysive shareholders as a Friday approval decision nears for Thelin, a treatment for pulmonary arterial hypertension, or PAH. The Food and Drug Administration has delayed two previous attempts to get the drug approved in the U.S., which has only added to the tension as the decision clock winds down.

If my email inbox is any indicator, there's considerable interest from retail investors in Encysive and its quest for approval of Thelin, mainly because the stock is cheap relative to the commercial opportunity for the drug, if approved. ...